BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
Launched by HOFFMANN-LA ROCHE · Oct 16, 2007
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • post-menopausal women;
- • \>=3 months daily or weekly alendronate or risedronate for treatment or prevention of post-menopausal osteoporosis.
- Exclusion Criteria:
- • inability to stand or sit in an upright position for at least 60 minutes;
- • hypersensitivity to bisphosphonates;
- • treatment with other drugs affecting bone metabolism;
- • abnormalities of the oesophagus, which delay oesophageal emptying.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Izmir, , Turkey
Split, , Croatia
Zagreb, , Croatia
Tuzla, , Bosnia And Herzegovina
Ankara, , Turkey
Antalya, , Turkey
Belgrade, , Serbia
Novi Sad, , Serbia
Rijeka, , Croatia
Adana, , Turkey
Skopje, , Macedonia, The Former Yugoslav Republic Of
Banja Luka, , Bosnia And Herzegovina
Gaziantep, , Turkey
Tirana, , Albania
Sarajevo, , Bosnia And Herzegovina
Slavonski Brod, , Croatia
Niska Banja, , Serbia
Aydin, , Turkey
Bursa, , Turkey
Denizli, , Turkey
Erzurum, , Turkey
Kayseri, , Turkey
Konya, , Turkey
Manisa, , Turkey
Samsun, , Turkey
Trabzon, , Turkey
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials